Zynex, Inc. (NASDAQ:ZYXI) CFO Daniel J. Moorhead Sells 10,000 Shares

Zynex, Inc. (NASDAQ:ZYXI - Get Free Report) CFO Daniel J. Moorhead sold 10,000 shares of the business's stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $7.88, for a total transaction of $78,800.00. Following the sale, the chief financial officer now directly owns 26,299 shares in the company, valued at approximately $207,236.12. This represents a 27.55 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Zynex Price Performance

Shares of ZYXI stock traded up $0.28 during trading hours on Friday, hitting $8.09. The company's stock had a trading volume of 50,575 shares, compared to its average volume of 68,037. The company has a current ratio of 3.94, a quick ratio of 3.15 and a debt-to-equity ratio of 1.66. The business has a fifty day moving average of $8.30 and a 200-day moving average of $8.37. Zynex, Inc. has a twelve month low of $7.15 and a twelve month high of $13.77. The stock has a market cap of $257.63 million, a price-to-earnings ratio of 53.93 and a beta of 0.49.

Zynex (NASDAQ:ZYXI - Get Free Report) last announced its earnings results on Thursday, October 24th. The company reported $0.07 EPS for the quarter, beating analysts' consensus estimates of $0.06 by $0.01. Zynex had a return on equity of 13.05% and a net margin of 2.49%. The firm had revenue of $49.97 million for the quarter, compared to analysts' expectations of $50.83 million. During the same quarter in the prior year, the firm earned $0.10 EPS. Zynex's quarterly revenue was up .1% on a year-over-year basis. As a group, equities research analysts anticipate that Zynex, Inc. will post 0.2 EPS for the current year.

Wall Street Analyst Weigh In

ZYXI has been the subject of several research analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $17.00 price objective on shares of Zynex in a research note on Friday, December 6th. Royal Bank of Canada cut their price target on Zynex from $12.00 to $11.00 and set an "outperform" rating for the company in a research note on Tuesday, October 8th.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Gladius Capital Management LP raised its holdings in Zynex by 53.4% in the 3rd quarter. Gladius Capital Management LP now owns 5,002 shares of the company's stock valued at $41,000 after acquiring an additional 1,742 shares during the last quarter. Investment Partners Asset Management Inc. purchased a new position in Zynex during the third quarter worth about $96,000. Hsbc Holdings PLC acquired a new stake in Zynex in the 2nd quarter worth about $113,000. Quest Partners LLC grew its holdings in Zynex by 646.7% in the 2nd quarter. Quest Partners LLC now owns 12,926 shares of the company's stock valued at $120,000 after buying an additional 11,195 shares during the period. Finally, Principal Financial Group Inc. increased its stake in shares of Zynex by 10.4% during the 2nd quarter. Principal Financial Group Inc. now owns 19,525 shares of the company's stock valued at $182,000 after acquiring an additional 1,846 shares during the last quarter. Institutional investors and hedge funds own 29.68% of the company's stock.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.